OBJECTIVE: To describe the design and first-round survey results of a trial of intensive sexually transmitted disease (STD) control to reduce HIV-1 incidence. STUDY DESIGN: Randomized, controlled, community-based trial in Rakai District, Uganda. METHODS: In this ongoing study, 56 communities were grouped into 10 clusters designed to encompass social/sexual networks; clusters within blocks were randomly assigned to the intervention or control arm. Every 10 months, all consenting resident adults aged 15-59 years are visited in the home for interview and sample collection (serological sample, urine, and, in the case of women, self-administered vaginal swabs). Sera are tested for HIV-1, syphilis, gonorrhea, chlamydia, trichomonas and bacterial vaginosis. Following interview, all consenting adults are offered directly observed, single oral dose treatment (STD treatment in the intervention arm, anthelminthic and iron-folate in the control arm). Treatment is administered irrespective of symptoms or laboratory testing (mass treatment strategy). Both arms receive identical health education, condom and serological counseling services. RESULTS: In the first home visit round, the study enrolled 5834 intervention and 5784 control arm subjects. Compliance with interview, sample collection and treatment was high in both arms (over 90%). Study arm populations were comparable with respect to sociodemographic and behavioral characteristics, and baseline HIV and STD rates. The latter were high: 16.9% of all subjects were HIV-positive, 10.0% had syphilis, and 23.8% of women had trichomonas and 50.9% had bacterial vaginosis. CONCLUSIONS: Testing the effects of STD control on AIDS prevention is feasible in this Ugandan setting.
RCT Entities:
OBJECTIVE: To describe the design and first-round survey results of a trial of intensive sexually transmitted disease (STD) control to reduce HIV-1 incidence. STUDY DESIGN: Randomized, controlled, community-based trial in Rakai District, Uganda. METHODS: In this ongoing study, 56 communities were grouped into 10 clusters designed to encompass social/sexual networks; clusters within blocks were randomly assigned to the intervention or control arm. Every 10 months, all consenting resident adults aged 15-59 years are visited in the home for interview and sample collection (serological sample, urine, and, in the case of women, self-administered vaginal swabs). Sera are tested for HIV-1, syphilis, gonorrhea, chlamydia, trichomonas and bacterial vaginosis. Following interview, all consenting adults are offered directly observed, single oral dose treatment (STD treatment in the intervention arm, anthelminthic and iron-folate in the control arm). Treatment is administered irrespective of symptoms or laboratory testing (mass treatment strategy). Both arms receive identical health education, condom and serological counseling services. RESULTS: In the first home visit round, the study enrolled 5834 intervention and 5784 control arm subjects. Compliance with interview, sample collection and treatment was high in both arms (over 90%). Study arm populations were comparable with respect to sociodemographic and behavioral characteristics, and baseline HIV and STD rates. The latter were high: 16.9% of all subjects were HIV-positive, 10.0% had syphilis, and 23.8% of women had trichomonas and 50.9% had bacterial vaginosis. CONCLUSIONS: Testing the effects of STD control on AIDS prevention is feasible in this Ugandan setting.
Entities:
Keywords:
Acquired Immunodeficiency Syndrome--prevention and control; Africa; Africa South Of The Sahara; Comparative Studies; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Hiv Infections--prevention and control; Infections; Measurement; Prevalence; Reproductive Tract Infections; Research Methodology; Research Report; Sexually Transmitted Diseases--prevention and control; Studies; Study Design; Treatment; Uganda; Viral Diseases
Authors: Elizabeth R Boskey; Shelly A Atherly-Trim; Patricia J O'Campo; Donna M Strobino; Dawn P Misra; P Misra Journal: Womens Health Issues Date: 2004 Jan-Feb
Authors: Matthew M Cousins; San-San Ou; Maria J Wawer; Supriya Munshaw; David Swan; Craig A Magaret; Caroline E Mullis; David Serwadda; Stephen F Porcella; Ronald H Gray; Thomas C Quinn; Deborah Donnell; Susan H Eshleman; Andrew D Redd Journal: J Clin Microbiol Date: 2012-07-11 Impact factor: 5.948
Authors: Samantha A Conroy; Oliver Laeyendecker; Andrew D Redd; Aleisha Collinson-Streng; Xiangrong Kong; Fredrick Makumbi; Tom Lutalo; Nelson Sewankambo; Noah Kiwanuka; Ronald H Gray; Maria J Wawer; David Serwadda; Thomas C Quinn Journal: AIDS Res Hum Retroviruses Date: 2010-10-06 Impact factor: 2.205
Authors: Chelsea B Polis; Maria J Wawer; Noah Kiwanuka; Oliver Laeyendecker; Joseph Kagaayi; Tom Lutalo; Fred Nalugoda; Godfrey Kigozi; David Serwadda; Ronald H Gray Journal: AIDS Date: 2010-07-31 Impact factor: 4.177
Authors: Jennifer A Wagman; Ronald H Gray; Neema Nakyanjo; Katherine A McClendon; Erika Bonnevie; Fredinah Namatovu; Grace Kigozi; Joseph Kagaayi; Maria J Wawer; Fred Nalugoda Journal: Eval Program Plann Date: 2017-12-24
Authors: Lindsay E Litwin; Frederick E Makumbi; Ronald Gray; Maria Wawer; Godfrey Kigozi; Joseph Kagaayi; Gertrude Nakigozi; Tom Lutalo; David Serwada; Heena Brahmbhatt Journal: J Acquir Immune Defic Syndr Date: 2015-07-01 Impact factor: 3.731
Authors: Manish Sagar; Oliver Laeyendecker; Sandra Lee; Jordyn Gamiel; Maria J Wawer; Ronald H Gray; David Serwadda; Nelson K Sewankambo; James C Shepherd; Jonathan Toma; Wei Huang; Thomas C Quinn Journal: J Infect Dis Date: 2009-02-15 Impact factor: 5.226
Authors: Jennifer A Wagman; Blake Charvat; Marie E Thoma; Anthony Ndyanabo; Fred Nalugoda; Joseph Ssekasanvu; Grace Kigozi; David Serwadda; Joseph Kagaayi; Maria J Wawer; Ronald H Gray Journal: Int J Public Health Date: 2016-09-13 Impact factor: 3.380